Seventeen @entity1 with advanced @entity1149 ( @entity1149 ) were entered on a combination chemotherapy protocol including @entity7324 and high-dose @entity900 . All @entity1 had measurable disease and had not previously received chemotherapy. All @entity1 entered were evaluable for @entity137 and response. Tumor regression was limited to one complete and one partial response (response rate, 11.7%; 95% confidence limits, 0 to 27%). The complete and partial response lasted 260 + and 82 days, respectively. For the 15 nonresponding @entity1 , the median time to disease progression was 76 days. Median survival was 141 days for the whole group. Significant toxic effects were @entity7324 -related @entity1897 and @entity900 -induced @entity391 . Myelosuppression was mild and manageable. The response for the @entity7324 - @entity900 combination observed in our study is inferior to that seen in a previous @entity7324 - @entity900 trial reported by others. Thus, the true value of this two-drug regimen in the treatment of @entity1149 remains to be established.

@entity7324 and high-dose XXXX in the treatment of advanced @entity1149 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity7324 :: ('MESH:D014751', 'Chemical') :: ['vindesine'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small-cell lung cancer'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity391 :: ('MESH:D014839', 'Disease') :: ['emesis'] @entity1897 :: ('MESH:D010523', 'Disease') :: ['peripheral neuropathy']
@entity900 :: (MESH:D002945,Chemical) :: ['cisplatin']
